Previous close | 2.8000 |
Open | 2.8000 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 3.50 |
Expiry date | 2026-01-16 |
Day's range | 2.8000 - 2.8000 |
Contract range | N/A |
Volume | |
Open interest | 30 |
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: